A Non-randomized Trial to Evaluate a TEst and Treat Intervention Integrating Novel Point-of-care Hepatitis C RNA Testing, Linkage to Nursing Care, and Peer-supported Delivery of HCV Testing and Treatment aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams
Phase of Trial: Phase IV
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary) ; Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms TEMPO
- 11 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 11 Nov 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.
- 11 Nov 2019 Status changed from not yet recruiting to recruiting.